Search
ZhiXiang JinTai:斯勒韦米单抗注射液获得药物临床试验批准通知书
2025-07-29 /
Read about 0 minute
Author：小编
ZhiXiang JinTai announced that the company had received the Approval Notice for Drug Clinical Trials issued by the National Medical Products Administration. The clinical trial application for its product in development, Sleremimab Injection , targeting passive immunity indications for suspected rabies virus exposure in children and adolescents aged 2 to 18 years old, has been approved. Sleremimab Injection is the world's first bispecific antibody for rabies passive immunity.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
